We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ACA’s Pricing, Formulary Pressures to Force Pipeline Reform, Push Novel Drugs
ACA’s Pricing, Formulary Pressures to Force Pipeline Reform, Push Novel Drugs
August 1, 2012
While the 2010 Affordable Care Act (ACA) is generally a revenue boon for drugmakers, the law presents pricing and formulary pressures that will force companies to steer toward less-saturated disease areas and better show the value of their products, experts say.